Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial-Reference-Cited by-同舟云学术

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Published:2016-12 Issue:12 Volume:4 Page:1004-1016
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Frías Juan P,Guja Cristian,Hardy Elise,Ahmed Azazuddin,Dong Fang,Öhman Peter,Jabbour Serge A

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference32 articles.

1. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015;Handelsman;Endocr Pract,2015

2. 7. Approaches to glycemic treatment;Diabetes Care,2016

3. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study;Jabbour;Diabetes Care,2014

4. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans;Nauck;Diabetes,2011

5. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists;Shaefer;Postgrad Med,2015

Cited by 330 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry;The American Journal of Medicine;2024-08

2. Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients;Diabetes, Obesity and Metabolism;2024-07-26

3. Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists;European Heart Journal;2024-07-10

4. Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis;The American Journal of the Medical Sciences;2024-07

5. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials;Journal of Cardiovascular Electrophysiology;2024-06-28